Ingram Cheung

Ingram Cheung is counsel in Goodwin’s Private Equity group in Hong Kong. His practice focuses on cross-border and domestic mergers and acquisitions, joint ventures, reorganizations as well as Hong Kong IPOs, takeovers and equity capital markets transactions.

Ingram’s recent experience includes representation of:

• TW Troy, a subsidiary of Tamarind Health, a Templewater portfolio company, on the proposed privatization of TalkMed Group, a Singapore-listed pan-Asian oncology-focused group 
• Templewater on the acquisition of Icon Group’s Hong Kong assets
• Biotheus in its sale to BioNTech for $800 million upfront, plus $150 million potential milestones
• Curon in its sale to Merck for $700 million upfront, plus $600 million potential milestones
• Templewater in the establishment and financing of a medical specialty clinics group, Tamarind Health
• LionRock Capital on its acquisition of Haglöfs AB, a leading outdoor performance brand, from ASICS Corporation
• Softbank Group Corp. as lead investor in its investment in the $280 million Series E financing round of Mapbox, a location platform powering navigation
• The management of ELEVATE in the sale of ELEVATE, an industry leader in ESG and supply chain services globally, by the Elevate management team and EQT to LRQA
• LionRock Capital in connection with its sale of a majority stake in leading shoe manufacturer and retailer Clarks 

Prior to joining Goodwin, Ingram was a senior associate in the Hong Kong office of Freshfields Bruckhaus Deringer.